COMPASS THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
COMPASS THERAPEUTICS, INC. (CMPX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-05
- COMPASS THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.90%.
- COMPASS THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -1.10%, a 173.33% decline from fiscal 2023.
- COMPASS THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 1.50%.
- COMPASS THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -2.70%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -0.90% 10-K · filed 2026-03-05 |
| 2024-12-31 | -1.10% 10-K · filed 2026-03-05 |
| 2023-12-31 | 1.50% 10-K · filed 2025-02-27 |
| 2022-12-31 | -2.70% 10-K · filed 2024-03-21 |
| 2021-12-31 | -1.00% 10-K · filed 2023-03-15 |
| 2020-12-31 | -0.50% 10-K · filed 2022-03-18 |
| 2019-12-31 | -0.10% 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |